CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02210858
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:54.777244+00:00
- Published At
- 2018-06-04T00:00:00+00:00
- Record Updated At
- 2018-06-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Accelerated Phase of Disease", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase of Disease", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Recurrent Disease"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-06-04"- protocolSection.identificationModule.nctId
"NCT02210858"- protocolSection.identificationModule.officialTitle
"Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.